Complement Therapeutics raises €5 million seed financing

Appoints Dr Rafiq Hasan as CEO

Merck completes acquisition of biopharma CDMO Exelead

Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science

CARsgen Therapeutics opens new U.S. cGMP facility for CAR T production

The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue

Syncona completes sale of Gyroscope to Novartis

The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope

Top five pharma looks to LifeSphere IDMP for regulatory readiness

ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness

Evonik invests in start-up to improve patient recovery after open-chest surgery

Evonik invests in start-up to improve patient recovery after open-chest surgery

Angus completes expansion of Louisiana site to include hydrochloride production

TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post